Business Strategy Merck Invests 70-Million Euros for Expanding Reagents Production in China

Source: Press release Merck KGaA 2 min Reading Time

Related Vendors

Merck has plans to expand the production capacity of reagents at its Nantong site in China. The move will help the firm’s customers to gain access to highly-purified reagents in order to carry out quality control and testing.

Merck is expanding production capacity for highly-purified reagents at its site in Nantong, China, a major transportation hub in the Yangtze River Delta region. (Source:  Merck KGaA)
Merck is expanding production capacity for highly-purified reagents at its site in Nantong, China, a major transportation hub in the Yangtze River Delta region.
(Source: Merck KGaA)

Nantong/China – Merck is expanding production capacity for highly-purified reagents at its site in Nantong, China, a major transportation hub in the Yangtze River Delta region. The approximate 70-million-euro investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons.

Merck and the Nantong Economic and Technological Development Area (Netda) recently signed the corresponding agreement in support of the expansion. “Continued growth of the life science and biopharma industries in China have increased demand for high-quality products and a more resilient supply chain,” said Jean-Charles Wirth, Head of Science & Lab Solutions, Merck Life Science.

“To ensure seamless supply for our customers, we have accelerated our expansion plan in China. In doing so, we continue to support the life science industry and enhance our ability to better serve our customers’ need for high-quality and reliable products.”

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

Merck will build a new reagent production plant at the Nantong site, which is expected to be operational by 2026. The facility will cover 40,000 square meters and offer high-performance products for quality control and testing to customers in the pharmaceutical, and industrial sectors, including food & beverage. The Netda site is already home to both the company’s Life Science and Healthcare business sectors.

The facility produces cell culture media for Life Science customers; Healthcare manufactures high-quality medicines that are on China's essential medicines list. It was opened in 2016 as part of Netda, one of the first national-level economic and technological development zones in China.

“Nantong serves as a major transportation hub in the Yangtze River Delta region, growing into an advanced manufacturing base. Netda has taken the lead in developing a first-class economic development zone with high-end industrial modernization, sound industry-city integration, and internationalization,” said Bao Delin, Deputy Secretary and Director of the Administration Committee, Netda, “Merck’s Life Science Center at Nantong, and its expansion marks an important milestone as the company continues to play an important role in Nantong’s transformation into an innovation-driven economy, with sustainable, high-quality growth at its core.”

(ID:49590115)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent